Skip to main content
. 2021 Dec 24;11:760405. doi: 10.3389/fonc.2021.760405

Figure 2.

Figure 2

MRI features of a secondary CNSL case during zanubrutinib monotherapy. (A) MRI depicts a homogeneously contrast-enhanced mass in the left cerebellum before zanubrutinib administration. (B, C) 7 and 14 days after zanubrutinib, the mass shrank and disappeared.